Paclitaxel

The present study deals with docking of Hematoporphrin with various anticancer drugs targeting enzymes. The targets used were PDB-ID 2Y3I, PDB-ID 3OZZ, PDB-ID 3UEN and PDB-ID 4O33. Hematoporphyrin docked with these enzymes and interactions between the enzyme and compound were measured and compared with standard Paclitaxel. The study concluded that, the compound (Hematoporphyrin) isolated from plant were high interactions with PDB-ID 4O33 when compared to standard.

The purpose of this study is to investigate the glycoprotein and efficacy of combination of paclitaxel along with Di allyl sulfide against skin cancer in experimental animals. Skin cancer is the most common form of human cancer. It is estimated that over 1 million new cases occur annually. The annual rates of all forms of skin cancer are increasing each year, representing a growing public concern. The most common warning sign of skin cancer is a change in the appearance of the skin, such as a new growth or a sore that will not heal. Skin cancer is caused by chemical carcinogens and Papilloma virus infection. Skin cancer was induced in rats by 7, 12 Di methyl benz(a) anthracene (DMBA) at the dosage of 5 µg was dissolved in 100µl and administered into experimental animals for 28 weeks. In this study, we demonstrated that combination of paclitaxel and Di allyl sulfide protects the rats from a lethal dose of DMBA for 30 days. The levels of glycoprotein in plasma, skin and liver were found to be increased in the cancer bearing animals when compared with control animals. Treatment of Paclitaxel along with Di allyl sulfide to cancer induced animals showed significantly decreased levels of glycoprotein levels when compared with cancer induced animals. The treatment with combination of paclitaxel and Di allyl sulfide effectively reduced glycoprotein levels. So, from the obtained results it is concluded that paclitaxel and Di allyl sulfide is capable of restoring the skin architecture. Key words: Paclitaxel, Di allyl sulfide, DMBA, Skin cancer.

At current 40% of the drugs were poorly soluble and were also called as “brick dust”. And the drugs which were belonging to the BCS CLASS II & IV were most eligible for this Nanosuspension technology. Here by using different methods we are reducing the particle size so the surface area will be increases ultimately it leads to increase in the bio availability. This instance was observed mostly in the case of anti-cancer drugs. Paclitaxel with 25% of Human Serum Albumin (HSA) showed very good results in terms of drug content, particle size, zeta potential and %CDR. Key words: Nanosuspension, Paclitaxel, Human Serum Albumin (HSA), High pressure homogenization.